^
Association details:
| Biomarker: | VHL mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Published date:
10/16/2023
Excerpt:
As indicated by Kaplan-Meier analysis, the patients with VHL mutation had significantly better OS in the MSKCC cohort (P < 0.001, median OS: 50 months vs 26 months)…VHL mutations might be a potential biomarker to predict the efficacy of immunotherapy for RCC.
Source:
Title:
Genomic alterations in metastatic renal cell carcinoma (mRCC): Impact on survival and clinical outcomes.
Published date:
02/13/2023
Excerpt:
2-yr OS for pts with a VHL mutation was 93% (95% CI: 82-97) vs. 68% (95%CI: 54-78) for pts without (p=0.01)... For pts with SETD2 mutations treated with IO/IO, mPFS was 0.7yrs (95%CI 0.3-1.2) vs. 1.4yrs (95%CI 0.8-1.9) for IO/TKI (p=0.01). For pts with BAP1 mutations treated with IO/IO, mPFS was 0.4yrs (95%CI 0.2-1.2) vs. NE (95%CI 0.2-NE) for IO/TKI (p=0.04)...VHL mutation was associated with improved 2-yr OS. Pts with SETD2 and BAP1 mutations treated with IO/TKI had improved mPFS...
DOI:
10.1200/JCO.2023.41.6_suppl.700
